Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  SkyePharma PLC    SKP   GB00B3BFNB64

SKYEPHARMA PLC (SKP)

10
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
12/15/2014 12/16/2014 12/17/2014 12/18/2014 12/19/2014 Date
330.25(c) 316(c) 316.25(c) 321.5(c) 322.25(c) Last
94 627 385 519 254 236 303 493 135 659 Volume
-2.08% -4.31% +0.08% +1.66% +0.23% Change
More quotes
Company
SkyePharma Plc is a UK based pharmaceutical company.It engages in the research and development, licensing, manufacturing, marketing and distribution of prescription pharmaceutical products.The company approves products in the areas of oral, inhalation and topical delivery.SkyePharma was founded by... 
Sector
Pharmaceuticals
Calendar
03/19Earnings Release
More about the company
Surperformance© ratings of SkyePharma PLC
Trading Rating : Investor Rating :
More Ratings
Chart SKYEPHARMA PLC
Duration : Period :
SkyePharma PLC Technical Analysis Chart | SKP | GB00B3BFNB64 | 4-Traders
Full-screen chart
Financials ( GBP)
Sales 2014 76,2 M
EBIT 2014 21,3 M
Net income 2014 -0,16 M
Finance 2014 6,98 M
Yield 2014 -
Sales 2015 102 M
EBIT 2015 31,9 M
Net income 2015 24,8 M
Finance 2015 32,1 M
Yield 2015 -
PER 2014 -
PER 2015 11,85
EV / Sales 2014 4,34x
EV / Sales 2015 3,01x
Capitalization 338 M
More Financials
Latest news on SKYEPHARMA PLC
12/01 SKYEPHARMA : Launches Flutiform In Spain, Italy; New Product In Japan
10/09 SKYEPHARMA : Says Sales Momentum Has Continued Since August
09/08 SKYEPHARMA : Partner Announces Phase III Flutiform Study Results
08/27 SKYEPHARMA : announces Interim Results 2014
08/23 SKYEPHARMA : Holding(s) in Company
08/22 SKYEPHARMA : Reports Interim Results Statement
08/21 SKYEPHARMA : *Skyepharma H1 Pretax Loss GBP18.1M Vs Pretax Loss GBP1.6M
08/21 SKYEPHARMA : *Skyepharma Says Prospects Remain In Line With Its Expectations
More news
Sector news
7h ago MERCK : buys new-cancer-drug firm
15h ago Fear factor fades as global M&A hits seven-year high
1d ago AstraZeneca CEO says new Pfizer bid unlikely - Swedish daily DI
More sector news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF